Literature DB >> 9731065

Lysis of plasma clots by urokinase-soluble urokinase receptor complexes.

A A Higazi1, K Bdeir, E Hiss, S Arad, A Kuo, I Barghouti, D B Cines.   

Abstract

Single-chain urokinase plasminogen activator (scuPA), the unique form secreted by cells, expresses little intrinsic plasminogen activator activity. scuPA can be activated by proteolytic cleavage to form a two-chain enzyme (tcuPA), which is susceptible to inhibition by plasminogen activator inhibitor type I (PAI-1). scuPA is also activated when it binds to its cellular receptor (uPAR), in which case the protein remains as a single chain molecule with less susceptibility to PAIs. Fibrin clots are invested with PAI-1 derived from plasma and from activated platelets. Therefore, we compared the fibrinolytic activity of complexes between scuPA and recombinant soluble uPAR (suPAR) to that of scuPA, tcuPA, and tcuPA/suPAR complexes. scuPA/suPAR complexes mediated the lysis of plasma-derived fibrin clots 14-fold more extensively than did equimolar concentrations of scuPA and threefold more extensively than did tcuPA or tcuPA/suPAR, respectively. The enhanced catalytic activity of scuPA/suPAR required that all three domains of the receptor be present, correlated with its PAI-1 resistance, was not dependent on fibrin alone, and required a plasma cofactor that was identified as IgG. Human IgG bound specifically to suPAR and scuPA/suPAR as determined by using affinity chromatography and immunoprecipitation. Plasma depleted of IgG lost most of its capacity to promote the fibrinolytic activity of scuPA/suPAR, and the activity of the complex was restored by adding plasma concentrations of purified IgG. These studies indicate that scuPA/suPAR can function as a plasminogen activator in a physiological milieu. Copyright 1998 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731065

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK.

Authors:  William M Armstead; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Brain Res       Date:  2010-12-20       Impact factor: 3.252

2.  Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice.

Authors:  Nuha Hijazi; Rami Abu Fanne; Rinat Abramovitch; Serge Yarovoi; Muhamed Higazi; Suhair Abdeen; Maamon Basheer; Emad Maraga; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Blood       Date:  2015-02-11       Impact factor: 22.113

3.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

4.  uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.

Authors:  William M Armstead; Douglas B Cines; Khalil H Bdeir; Yasmina Bdeir; Sherman C Stein; Abd Al-Roof Higazi
Journal:  J Cereb Blood Flow Metab       Date:  2008-12-03       Impact factor: 6.200

5.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.

Authors:  Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2009-07-16       Impact factor: 9.776

6.  Blood-brain barrier permeability and tPA-mediated neurotoxicity.

Authors:  Rami Abu Fanne; Taher Nassar; Sergei Yarovoi; Anwar Rayan; Itschak Lamensdorf; Michael Karakoveski; Polianski Vadim; Mahmud Jammal; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neuropharmacology       Date:  2010-01-06       Impact factor: 5.250

7.  uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK.

Authors:  William M Armstead; Douglas B Cines; Khalil Bdeir; Irina Kulikovskaya; Sherman C Stein; Abd Al-Roof Higazi
Journal:  Brain Res       Date:  2008-07-08       Impact factor: 3.252

8.  Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK.

Authors:  William M Armstead; Amy J Christine; Abd Al-Roof Higazi; Douglas B Cines
Journal:  J Neurotrauma       Date:  2008-11       Impact factor: 5.269

9.  Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.

Authors:  J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi; William M Armstead
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-23       Impact factor: 4.733

Review 10.  Mesothelial cells in tissue repair and fibrosis.

Authors:  Steven E Mutsaers; Kimberly Birnie; Sally Lansley; Sarah E Herrick; Chuan-Bian Lim; Cecilia M Prêle
Journal:  Front Pharmacol       Date:  2015-06-09       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.